HiLung Inc.

HiLung was founded in 2020 to dramatically accelerate respiratory drug discovery and development, leveraging our ground-breaking human respiratory cell differentiation and engineering technology. We offer stable and scalable human respiratory cells and organoids recapitulated from iPSCs, coupled with assays and analytics as needed, in multiple formats unattainable with biopsied primary cells. Applications include toxicology studies as well as target identification and validation studies for human infections (including COVID-19) and other respiratory diseases such as pulmonary fibrosis and lung cancer.

Also, we are developing respiratory drugs for own pipelines leverage the R&D platforms with our cell engineering technologies and comprehensive knowledges for respiratory disease mechanisms.